In March 2025, the company announced new options for a direct-to-buyer supplying of its Wegovy weight loss drug. The company recognized a whole new pharmacy, identified as NovoCare, which would demand prospects $499 every month for use of the drug, less than 50 % the expense of the drug via other pharmaceutical distribution networks.[fifty three]Ry